Enthused by PhII autoimmune data, J&J kept Momenta waiting in the lead-up to $6.5B buyout
Momenta had been talking to J&J for well over a year about a potential partnership when it was due to release Phase II data for its lead drug, nipocalimab (M281), in myasthenia gravis. Having established a line of contact during the 2019 JP Morgan conference, Momenta CEO Craig Wheeler raised the possibility of a buyout in October. For months, J&J kept asking more questions about both nipocalimab and a second compound, M254.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.